Clene Inc.
HealthcareNASDAQ:CLNN · NASDAQ Capital Market
+$0.31 today
Vol 0.08M · Avg 0.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
148.8%
avg -751.9%
ROIC
-188.6%
avg -94.7%
ROA
-144.4%
avg -67.0%
Analysis
ROE is currently the strongest return metric at 148.8% versus its period average of -751.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert Etherington | Chief Executive Officer, President & Director | $547,243.00 | — | 59 | $75,000.00 | 0.73% |
Mark G. Mortenson | Chief Science Officer | $441,069.00 | — | 68 | $75,000.00 | 0.73% |
Morgan R. Brown | Chief Financial Officer | $324,164.00 | — | 58 | $35,000.00 | 0.34% |
Mary Anne Mcneil | Head of Human Resources | — | — | — | — | — |
Jerry Miraglia | General Counsel & Corporate Secretary | — | — | — | — | — |
Benjamin Greenberg | Head of Medical | — | — | — | — | — |
Michael T. Hotchkin | Chief Development Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$216,664.50
Sells
63
$5.80M
Net Sentiment
$5.58M
Net selling
Most Active
Ugwumba Chidozie
62 transactions
1–10 of 64
Analysis
Insiders reported 1 buys worth $216,664.50 and 63 sells worth $5.80M over the last 12 months. That adds up to net selling of $5.58M. Ugwumba Chidozie was the most active insider with 62 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +106.7% (9yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +106.7% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$158.38M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
Context Therapeutics Inc.
NASDAQ:CNTX
$127.71M
Coya Therapeutics, Inc.
NASDAQ:COYA
$86.31M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Who manages CLNN?
Clene Inc. (CLNN) lists 7 active executives. The top listed executive is Robert Etherington, Chief Executive Officer, President & Director.
Are CLNN insiders buying or selling?
Recent insider activity shows net buying of $5.24M.
Explore More
Continue the stock analysis
Jump to another research area for this company.